Last reviewed · How we verify

Brinavess (Vernakalant) — Competitive Intelligence Brief

Brinavess (Vernakalant) (Brinavess (Vernakalant)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Atrial-selective antiarrhythmic agent. Area: Cardiovascular.

marketed Atrial-selective antiarrhythmic agent Atrial potassium channels (Kv1.5, Kv4.3) and sodium channels Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Brinavess (Vernakalant) (Brinavess (Vernakalant)) — Medical University of Vienna. Vernakalant blocks atrial-selective potassium and sodium channels to rapidly restore normal heart rhythm in patients with atrial fibrillation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Brinavess (Vernakalant) TARGET Brinavess (Vernakalant) Medical University of Vienna marketed Atrial-selective antiarrhythmic agent Atrial potassium channels (Kv1.5, Kv4.3) and sodium channels

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Atrial-selective antiarrhythmic agent class)

  1. Medical University of Vienna · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Brinavess (Vernakalant) — Competitive Intelligence Brief. https://druglandscape.com/ci/brinavess-vernakalant. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: